Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 10 |
| List of Tables | 10 | 1 |
| List of Figures | 11 | 1 |
| Introduction | 12 | 1 |
| Global Markets Direct Report Coverage | 12 | 1 |
| Human Papillomavirus (HPV) Associated Cancer Overview | 13 | 1 |
| Therapeutics Development | 14 | 2 |
| Pipeline Products for Human Papillomavirus (HPV) Associated Cancer Overview | 14 | 1 |
| Pipeline Products for Human Papillomavirus (HPV) Associated Cancer Comparative Analysis | 15 | 1 |
| Human Papillomavirus (HPV) Associated Cancer Therapeutics under Development by Companies | 16 | 3 |
| Human Papillomavirus (HPV) Associated Cancer Therapeutics under Investigation by Universities/Institutes | 19 | 1 |
| Human Papillomavirus (HPV) Associated Cancer Pipeline Products Glance | 20 | 3 |
| Late Stage Products | 20 | 1 |
| Clinical Stage Products | 21 | 1 |
| Early Stage Products | 22 | 1 |
| Human Papillomavirus (HPV) Associated Cancer Products under Development by Companies | 23 | 3 |
| Human Papillomavirus (HPV) Associated Cancer Products under Investigation by Universities/Institutes | 26 | 1 |
| Human Papillomavirus (HPV) Associated Cancer Companies Involved in Therapeutics Development | 27 | 37 |
| Admedus Ltd | 27 | 1 |
| Advaxis, Inc. | 28 | 1 |
| Antigen Express, Inc. | 29 | 1 |
| Bionor Pharma ASA | 30 | 1 |
| BioNTech AG | 31 | 1 |
| Cancer Research Technology Limited | 32 | 1 |
| Cell Medica Limited | 33 | 1 |
| Etubics Corporation | 34 | 1 |
| EyeGene, Inc. | 35 | 1 |
| Formune S.L. | 36 | 1 |
| Genexine, Inc. | 37 | 1 |
| Genticel S.A. | 38 | 1 |
| iBio, Inc. | 39 | 1 |
| Immunovaccine, Inc. | 40 | 1 |
| Inovio Pharmaceuticals, Inc. | 41 | 1 |
| Inthera Bioscience AG | 42 | 1 |
| Johnson &Johnson | 43 | 1 |
| Karyopharm Therapeutics, Inc. | 44 | 1 |
| Kite Pharma, Inc. | 45 | 1 |
| MedImmune, LLC | 46 | 1 |
| Novartis AG | 47 | 1 |
| Onconova Therapeutics, Inc. | 48 | 1 |
| Oryx GmbH &Co. KG | 49 | 1 |
| Profectus BioSciences, Inc. | 50 | 1 |
| Selecta Biosciences, Inc. | 51 | 1 |
| Shantha Biotechnics Limited | 52 | 1 |
| Sirnaomics, Inc. | 53 | 1 |
| Theravectys SA | 54 | 1 |
| THEVAX Genetics Vaccine USA Inc | 55 | 1 |
| Tomegavax, Inc. | 56 | 1 |
| Transgene SA | 57 | 1 |
| UbiVac, LLC | 58 | 1 |
| Vaccibody AS | 59 | 1 |
| Vault Pharma Inc. | 60 | 1 |
| Virometix AG | 61 | 1 |
| ViroStatics srl | 62 | 1 |
| VLPbio | 63 | 1 |
| Human Papillomavirus (HPV) Associated Cancer Therapeutics Assessment | 64 | 9 |
| Assessment by Monotherapy Products | 64 | 1 |
| Assessment by Target | 65 | 2 |
| Assessment by Mechanism of Action | 67 | 2 |
| Assessment by Route of Administration | 69 | 2 |
| Assessment by Molecule Type | 71 | 2 |
| Drug Profiles | 73 | 89 |
| ABI-1968 Drug Profile | 73 | 1 |
| AEH-10p Drug Profile | 74 | 1 |
| alpelisib Drug Profile | 75 | 3 |
| Antibodies to Target E6 for HPV Associated Cancer Drug Profile | 78 | 1 |
| Antibodies to Target E7 for HPV Associated Cancer Drug Profile | 79 | 1 |
| BVAC-C Drug Profile | 80 | 1 |
| Cellular Immunotherapy for HPV Associated Cancers Drug Profile | 81 | 1 |
| Cellular Immunotherapy to Target HPV-16 E6 Protein for Cancer Drug Profile | 82 | 2 |
| Cellular Immunotherapy to Target HPV-16 E7 Protein for Head and Neck Cancer and Cervical Cancer Drug Profile | 84 | 2 |
| CerviVax Drug Profile | 86 | 1 |
| CMD-004 Drug Profile | 87 | 1 |
| DPV-001 Drug Profile | 88 | 2 |
| DPXE-7 Drug Profile | 90 | 1 |
| EDA-HPVE7 Drug Profile | 91 | 1 |
| EG-HPV Drug Profile | 92 | 1 |
| Enzymes to Inhibit HPV E7 for Human Papillomavirus Related Cervical Cancer Drug Profile | 93 | 1 |
| ETBX-041 Drug Profile | 94 | 1 |
| GTL-001 Drug Profile | 95 | 3 |
| GTL-002 Drug Profile | 98 | 1 |
| GX-188E Drug Profile | 99 | 2 |
| human papillomavirus (7-valent) vaccine Drug Profile | 101 | 1 |
| human papillomavirus [Serotype 16] vaccine Drug Profile | 102 | 1 |
| human papillomavirus [serotypes 16] vaccine Drug Profile | 103 | 1 |
| human papillomavirus vaccine Drug Profile | 104 | 1 |
| human papillomavirus vaccine Drug Profile | 105 | 1 |
| human papillomavirus vaccine Drug Profile | 106 | 1 |
| human papillomavirus vaccine [types 6, 11, 16, 18] biosimilar Drug Profile | 107 | 1 |
| INO-3106 Drug Profile | 108 | 1 |
| INO-3112 Drug Profile | 109 | 2 |
| Lm-LLO-ISG15 Drug Profile | 111 | 2 |
| LN-145 Drug Profile | 113 | 2 |
| Monoclonal Antibody to Target E6 and E7 Proteins for Oncology Drug Profile | 115 | 1 |
| NIT-02 Drug Profile | 116 | 1 |
| NP-001 Drug Profile | 117 | 1 |
| PVX-01 Drug Profile | 118 | 1 |
| Recombinant Vector Vaccine to Target E7 for HPV Associated Cancers Drug Profile | 119 | 1 |
| Recombinant Vector Vaccine to Target E7 for HPV Associated Cervical Intraepithelial Neoplasia Drug Profile | 120 | 1 |
| rigosertib sodium Drug Profile | 121 | 11 |
| sdCMV-002 Drug Profile | 132 | 1 |
| SEL-701 Drug Profile | 133 | 1 |
| Small Molecule to Inhibit CDK4, CDK6 and CDK9 for HPV Associated Cancers Drug Profile | 134 | 1 |
| Small Molecules for Solid Tumors and HPV Associated Cancer Drug Profile | 135 | 1 |
| STP-909 Drug Profile | 136 | 1 |
| Subunit Vaccine for HPV Associated Cervical Cancer Drug Profile | 137 | 1 |
| Synthetic Peptide to Inhibit HPV E6 Protein for HPV Associated Cancer Drug Profile | 138 | 1 |
| TA-CIN Drug Profile | 139 | 1 |
| TG-4001 Drug Profile | 140 | 2 |
| TVGV-1 Drug Profile | 142 | 1 |
| Vacc-HPV Drug Profile | 143 | 1 |
| Vaccine for HIV and HPV Associated Cancer Drug Profile | 144 | 1 |
| Vaccine for HPV Associated Cancer Drug Profile | 145 | 1 |
| Vaccine for HPV Associated Cancers Drug Profile | 146 | 1 |
| Vaccine for HPV Associated Cervical Cancer Drug Profile | 147 | 1 |
| Vaccine for HPV Associated Cervical Cancer Drug Profile | 148 | 1 |
| Vaccine for HPV Associated Cervical Cancer Drug Profile | 149 | 1 |
| Vaccine for HPV Associated Skin Cancer Drug Profile | 150 | 1 |
| Vaccine for Human papillomavirus Associated Cervical Cancer Drug Profile | 151 | 1 |
| VB-1016 Drug Profile | 152 | 2 |
| verdinexor Drug Profile | 154 | 1 |
| VGX-3100 Drug Profile | 155 | 3 |
| Vicoryx Drug Profile | 158 | 1 |
| VMT-2 Drug Profile | 159 | 1 |
| VPI-241 Drug Profile | 160 | 1 |
| Vvax-001 Drug Profile | 161 | 1 |
| Human Papillomavirus (HPV) Associated Cancer Dormant Projects | 162 | 2 |
| Human Papillomavirus (HPV) Associated Cancer Product Development Milestones | 164 | 7 |
| Featured News &Press Releases | 164 | 1 |
| Jul 06, 2016: Genticel Appoints Eumedix as Strategic Advisor to Support Company S Access to Innovative Drug Candidates | 164 | 1 |
| Jun 23, 2016: Genticel Reports 18 Month Interim Analysis of GTL001 Phase 2 Trial in HPV16/18 Infected Women | 164 | 1 |
| Jun 15, 2016: Genticel to Present Preclinical Results of GTL002 at EUROGIN 2016 Congress in Salzburg, Austria | 165 | 1 |
| Jun 01, 2016: Genticel Announces Publication in Clinical Cancer Research of Phase 1 Trial Results Supporting Safety, Tolerability and Immunogenicity of GTL001 | 165 | 1 |
| Apr 20, 2016: Genticel Reports Additional Results at 12 Months From Phase 2 Trial of HPV Immunotherapeutic Candidate, GTL001 | 166 | 1 |
| Oct 01, 2015: Kite Pharma Announces Peer-Reviewed Publication of T Cell Receptor Based Product Candidate to Treat HPV-Associated Cancers | 167 | 1 |
| Jun 01, 2015: Genticel Announces Positive Preclinical Proof of Concept Results of GTL002, Its New Multivalent HPV Therapeutic Vaccine Candidate Based on Company's Versatile Vaxiclase Platform | 168 | 1 |
| Apr 09, 2015: Inovio Pharmaceuticals' HPV Immunotherapy Recognized as "Best Therapeutic Vaccine" by World Vaccine Congress | 169 | 1 |
| Mar 05, 2014: Generex Subsidiary Antigen Express Receives Patents for Vaccines Targeting HPV Induced Cancers and Influenza | 169 | 1 |
| Feb 28, 2012: Coridon To Develop New HPV Therapeutic Vaccine | 170 | 1 |
| Appendix | 171 | 2 |
| Methodology | 171 | 1 |
| Coverage | 171 | 1 |
| Secondary Research | 171 | 1 |
| Primary Research | 171 | 1 |
| Expert Panel Validation | 171 | 1 |
| Contact Us | 171 | 1 |
| Disclaimer | 172 | 1 |